Allogene Therapeutics Inc (NYSE:ALLO) Q2 2019 Earnings Conference Call - Final Transcript
Aug 07, 2019 • 08:30 am ET
Good morning, ladies and gentlemen. And thank you for standing by, and welcome to Allogene Therapeutics Second Quarter 2019 Conference Call. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]
I would now like to turn the conference over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.
Thank you, operator, and good morning. Before market opened today, Allogene issued a press release to provide the corporate update and financial results for the quarter ending June 30, 2019. The press release is available on our website at www.allogene.com. We will be discussing our ALLO-715 Phase 1 clinical trial protocol today and is posted on our website. A slide which provides an overview of the trial. This can be found in the Investors section under news and events.
We remind listeners that today's call is being webcast on our website and will be available for replay. Joining me on the call today are Dr. David Chang, President and Chief Executive Officer; and Dr. Eric Schmidt, Chief Financial Officer.
During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, regulatory filings, future research and development efforts and manufacturing capabilities, among other things. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the Securities and Exchange Commission, including our Form 10-K for the quarter ended March 31, 2019, as well as our upcoming Form 10-Q for the quarter ended June 30, 2019. You are cautioned not to place undue reliance on these forward-looking statements, and the company disclaims any obligation to update such statements.
I'll now turn the call over to Dr. David Chang.
Thank you, Christine. Good morning. Thank you all for joining our second quarter earnings call. We are very pleased to be speaking with you this morning to review our recent progress. The second quarter was an important one on many fronts from advancing our pipeline, to designing our state-of-the-art manufacturing facility and recruiting highly skilled employees who are passionate about bringing Allogeneic cell therapy to patients. To that end, our full-time headcounts not had grown to over 170 employees.
Top of mind for many of you is the progress we are making in our clinical programs. The second quarter marked the initiation of Allogene's first sponsored clinical trial as we began treating patients in our ALPHA study, a Phase 1/2 study of ALLO-501 in relapsed/refractory non-Hodgkin lymphoma or NHL. We are pleased with how this dose escalation study is progressing, and believe that success in this trial has the potential to derisk our anti-CD19 AlloCAR program, as well AlloCAR T platform more broadly. Including the use of our proprietary lymphodepletion strategy that is